Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2237273 | 0.92 | ACE (0.36) | ACEFOLH1DPP8DPP7MAPT | |
| SCHEMBL2381593 | 0.91 | ACE (0.35) | ACEFOLH1DPP8DPP7MAPT | |
| SCHEMBL2233508 | 0.91 | ACE (0.35) | ACEFOLH1DPP8DPP7MAPT | |
| SCHEMBL2235331 | 0.90 | ACE (0.38) | ACEFOLH1DPP8DPP7MAPT | |
| SCHEMBL2238348 | 0.84 | LMNA (0.39) | ACE | |
| SCHEMBL2233582 | 0.82 | ACE (0.35) | ACEFOLH1DPP8DPP7MAPT | |
| SCHEMBL2233645 | 0.81 | ACE (0.38) | ACEMAPT | |
| SCHEMBL2234466 | 0.81 | MEN1 (0.47) | ACE | |
| SCHEMBL2236787 | 0.81 | MEN1 (0.47) | ACE | |
| SCHEMBL2238532 | 0.81 | MEN1 (0.47) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2361910-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAF1, TAF5, TAF11 | ACE 473/4885FOLH1 4483/4885DPP8 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.